Research programme: immunophilin ligands - Pfizer

Drug Profile

Research programme: immunophilin ligands - Pfizer

Alternative Names: 3-Normeridamycin

Latest Information Update: 19 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Macrolides
  • Mechanism of Action Immunophilin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 07 Aug 2009 Preclinical development is ongoing in USA
  • 18 Apr 2008 Pharmacodynamics data from a preclinical study presented at the 235th American Chemical Society National Meeting (235th-ACS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top